Senate Excludes Orphan Cures Act From Trump's Tax Bill, Impacting Biopharma

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

The Senate Finance Committee’s version of a massive tax cut package omits some PBM reforms and other provisions from the House-passed version that change how orphan drugs are treated under the Medicare price negotiation program ...

Senate Excludes Orphan Cures Act from Trump's Tax Bill, Impacting Biopharma

The biopharma industry faced a setback as the Senate’s version of the One Big Beautiful Bill Act, linked to President Donald Trump’s tax reforms, excluded the Orphan Cures Act, a provision aimed at amending an Inflation Reduction Act (IRA) clause affecting rare disease treatments. This bipartisan act sought to exempt drugs with multiple rare disease indications from Medicare’s price negotiations, an exemption currently applicable only to drugs t…